GeneNews Bluttest zur Früherkennung von Krebs

Seite 1 von 1
neuester Beitrag: 11.06.19 09:08
eröffnet am: 12.04.19 08:07 von: bmuesli Anzahl Beiträge: 12
neuester Beitrag: 11.06.19 09:08 von: bmuesli Leser gesamt: 1485
davon Heute: 2
bewertet mit 0 Sternen

12.04.19 08:07

417 Postings, 2169 Tage bmuesliGeneNews Bluttest zur Früherkennung von Krebs

Hallo zusammen, da es zu GeneNews noch kein Forum hier gibt, habe ich mir erlaubt dieses hier zu eröffnen. Man hat wohl mit Colon Sentry eine Bluttest zur Erkennung von Darmkrebs. Der Aktienkurs ist allerdings die letzten Monate schon sehr gut gelaufen aber dennoch sehe ich hier durchaus noch Potential nach oben. und hier mal die

Investor Präsentation

Produkt Pipeline ZitatAntwort


12.04.19 10:14

417 Postings, 2169 Tage bmuesliZahlen

Company Builds Momentum with Launch of Patient Directed Cancer Testing; Gains Ground in Population Health Initiatives with Health Systems and Employers; and Plans are Underway for Validation of Next-Generation Cancer Panel - Aristotle®

TORONTO, ON / ACCESSWIRE / April 3, 2019 / GeneNews Limited (TSX: GEN) (''GeneNews'' or the ''Company'') today announced operational and financial results for the three-month and twelve-month periods ended December 31, 2018 and provided a progress update on its business.

According to the Company's CEO, James R Howard-Tripp, ''2018 was an 'establishing momentum' year for us and we are excited about the business development initiatives we've been working on for two-plus years coming to successful conclusion in 2019. The most significant and exciting development during 2018 was the decision to return to our roots as a life sciences company and refocus our efforts on the validation and go-to-market strategy for our next-generation test, Aristotle®.''

Aristotle® is built on the Company's proven and proprietary Sentinel Principle Technology Platform and can test for ten cancers from a single sample of blood. This is a high impact market with sales potential estimates of $17 - $35 Billion.

Aristotle has high sensitivity and specificity across these multiple cancers and this same technology was validated in a 10,000 patient clinical trial and, has now been used in over 100,000 patients in North America, to aid in the early detection of Colorectal Cancer (ColonSentry®).

During 2018, the Company launched a business development initiative to target larger health systems that can work with high-risk populations and follow-up with patients who have elevated test scores. The Company has experienced early success with a Midwest hospital system that is utilizing all four blood-based cancer biomarker tests in three high-risk patient populations.

Another significant development in 2018 was building the partnerships and infrastructure required to support a patient directed testing model. GeneNew's business development team secured a national provider network and a robust blood draw network that includes a combination of more than 8,000 draw sites and mobile phlebotomists.

The Company also strengthened efforts to market to Concierge physicians whose practice models are more likely to attract patients who want to be proactive about their health and are willing to participate in advanced biomarker testing for early cancer detection. These patients have more disposable income and are willing to pay out-of-pocket for these tests vs. go through their insurance. It is this type of educated healthcare consumer that the Company will be targeting for the new Patient Directed Testing model announced earlier this month.

''Although Concierge practices are very much on our radar screen, small practices are anticipated to be only about 10% of the Company's volume,'' Says Howard-Tripp. ''We anticipate that telehealth/patient directed testing, screening of high-risk employees in self-funded employer health plans, and large healthcare system will each account for approximately 30% of test volume and revenues in 2019.''

Moving forward, a large part of the Company's commercial strategy will focus on larger opportunities that can create high volumes of tests as well as generate direct revenue from immediate payment or flat fee invoicing. The Company will therefore increase its efforts to reach large, self-funded employers, 75% of which cited high-cost claimants as one of the top drivers of rising health care. The number one catastrophic claim for employers in 2018 was Cancer, and the CDC predicts that by 2020 Cancer will be the leading cause of death in the United States.

''Our four blood-based tests for early detection of colorectal, prostate, breast and lung cancer are leading the way to adoption of early diagnosis models. Imagine what Aristotle® will do when we can leverage it into the commercial relationships we are building. This, we believe, will be in about two-year's time,'' said Howard-Tripp. ''We are excited about our future.''

Q4 2018 Financial Results

All amounts are expressed in U.S. dollars unless otherwise stated and results are reported in accordance with International Financial Reporting Standards.

For the three-month period ended December 31, 2018, we reported revenue of $0.07 million and a consolidated net loss of $0.7 million, or $0.03 loss per common share, as compared with revenue of $0.05 million and a consolidated net loss of $0.4 million, or $0.03 loss per common share, for the three-month period ended December 31, 2017. The $0.3 million increased loss results from the $1.4 million impact of the change in fair value of notes payable, $0.1 million change in fair value of conversion liability, the $0.1 million increase in finance costs offset by $0.2 million lower general and administrative expenses and $1.1 million revaluation of warrants.

Die Zahlen hauen einem natürlich nicht gerade vom Hocker aber an der Börse wird ja Zukunft gehandelt. Und wenn man sieht wie euphorisch manche bei Epigenomics si´nd.  

12.04.19 17:22

417 Postings, 2169 Tage bmuesliGrund der Wiederbelebung Mr. James Howard-Tripp reports GENENEWS EXPANDS COVERAGE BY COMMERCIAL HEALTH INSURANCE NETWORKS GeneNews Ltd. has entered into an agreement with Three Rivers Provider Network for Innovative Diagnostic Laboratory LLP's tests for early cancer detection. Three Rivers Provider Network is a rapidly growing proprietary provider network with 200 million lives that have access to Innovative Diagnostic Laboratory services through the TRPN network of providers, hospitals and ancillary facilities. The ability to address diagnostic gaps in early cancer detection saves lives and money for providers and patients in this network through access to proprietary Innovative Diagnostic Laboratory tests. GeneNews/Innovative Diagnostic Laboratory has also entered into an agreement with MultiPlan Inc., one of the most comprehensive providers of health care cost management solutions that includes primary, complementary and out-of-network strategies for managing the financial risks associated with health care claims. MultiPlan contracts with 900,000 health care providers across the United States and has an estimated 60 million consumers accessing MultiPlan network products. "We are pleased to announce that we are successfully establishing agreements with regional and national commercial health insurance networks, like Three Rivers and MultiPlan, resulting in expanded access to our four early cancer diagnostic tests -- ColonSentry, EarlyCDT-lung, Prostate Health Index (PHI) and BreastSentry," commented James Howard-Tripp, chairman and chief executive officer of GeneNews. "This expanded access is benefitting all parties -- patients, their providers and ourselves -- as more efficient processing of claims becomes fully established." GeneNews/Innovative Diagnostic Laboratory is in discussion with several other regional and national commercial health insurance networks as well as self-financed employer plans. Additionally, GeneNews is preparing for a very active first quarter in 2019, with plans already in place for screening of high-risk employee groups, implementation of screening within large health care groups and collaborating with one or more large physician networks. In addition, GeneNews will begin initial rollout of the rebranding of the company, which, together with an expanded direct-to-consumer focus, will allow the company to more fully provide its early cancer diagnostic tests to the many patients who contact it. Second convertible security financing agreement GeneNews has also entered into a second convertible security financing agreement with Lind Asset Management XI LLC for $500,000 in convertible securities. Under the terms of the agreement, Lind Asset Management will advance $500,000, less a closing fee of $35,000, in consideration for the issuance by the company of a convertible security with a face value of $600,000, which is expected to occur within 10 business days, subject to satisfaction of certain closing conditions. "This injection of cash is welcome and will allow the company to accelerate its initiatives with large health care providers to increase the rate of implementation, as well as begin rebranding. We are very pleased to have the partners within Lind continue to support us in this way," commented Mr. Howard-Tripp. The convertible security has a 30-month term from the date of issuance and bears interest of 8 per cent per year. The company's obligations under the agreement are secured by all of the company's present and after-acquired property, other than intellectual property, including a pledge of its equity interests in its subsidiaries. In addition, the company's indirect subsidiary, Innovative Diagnostic Laboratory, has pledged its present and after-acquired property, other than intellectual property. Lind Asset Management may convert the convertible security in monthly instalments over the term at a conversion price equal to 85 per cent of the five-day trailing volume-weighted average price of the company's common shares on the Toronto Stock Exchange prior to the date that notice of conversion is provided by Lind Asset Management. The agreement contains restrictions on the amount of the convertible security that may be converted in any particular month and how many common shares of GeneNews Lind Asset Management may hold at any given time. Lind Asset Management is entitled to accelerate its conversion right to the full amount of the face value or demand repayment of the face value of the convertible security in cash upon a default and other specified events. To the extent that the full face value of the convertible security has not been converted at maturity, the balance of the face value is to be paid in cash at the end of the 30-month term. The company has the option to buy back the convertible security in cash at any time by paying a buyback premium equal to 5 per cent of the outstanding balance of the convertible security. In addition, the company has agreed to issu

die News ist zwar von Dezember 2018 aber ich vermute mal dies war der Grund für den Anstieg in den letzten Monaten

13.04.19 15:45

417 Postings, 2169 Tage bmuesli30 Millionen sehr optimistisch
habe mal eine Anfrage gestellt und hier die Antwort. Allerdings scheinen mir 30 Millionen ein wenig zu optimistisch. Man kann es sich auch in obigem Link anhören jedoch muss man da scheinbar ein Abo haben
Dear Mr xxx; Thanks for your interest in GeneNews; As Financial Communication advisor to GEN ; feel free to contact me any time; About you question:
1.How many stocks are currently out there? The company has 178 261 234 shares issues; You can find in the sedar filling management discussion all the detail about the options - warrants and convertible notes or debenture in the following link:
2. How many shares are currently held by management and major investors? Management control around 15% on a fully diluted base Major investors control another approximative 25%+
3. What do you expect for annual sales in the future? As the power point and last conference call - GEN expect around 30m in sales for present fiscal years Find the link of the last conference call: Sincerely

GeneNews Bluttest zur Früherkennung von Krebs | - Vollständige Diskussion unter:  

14.04.19 08:53

417 Postings, 2169 Tage bmuesliTelemedizin

GeneNews Launches First Telehealth Initiative for Patient Directed Testing

Thursday, March 28, 2019 8:55 AM

Company to Capitalize on $16.7 Billion Telehealth Market by Offering Patient Directed Testing Through an Independent Provider Network

TORONTO, ON / ACCESSWIRE / March 28, 2019 / GeneNews Limited (TSX: GEN) ("GeneNews" or the "Company"), a life sciences company specializing in blood-based biomarker tests for early cancer detection, has launched the first of several initiatives to make patient directed testing available nationwide.

GeneNews has partnered with PWNHealth, a national virtual care company that enables access to physicians who will facilitate and authorize diagnostic testing and provide guidance with test results. Patients will be able to purchase and initiate testing through an online portal at MyCancerRisk.Com where they can pay one flat fee for the test, the physician order and consult, and phlebotomy (blood draw) services.

Once an order is submitted, GeneNews will connect the patient with a physician in PWN's network who can prescribe the test and discuss the results with patients. Patients are advised to share their test reports with their regular healthcare providers so their results can be integrated into their existing medical records as well as current or future treatment plans.

In addition to providing access to a national provider network, GeneNews has built a national blood draw network that includes a combination of more than 8,000 draw sites and mobile phlebotomists through various partnerships with clinical laboratories.

"This initiative is something we've been working toward for two years," said James Howard-Tripp, CEO of GeneNews. "We now have all the pieces in place - the right tests, the physician network, nationwide blood draw capabilities and an IT infrastructure to launch a seamless patient directed testing model." Howard-Tripp adds, "We get inquiries from patients every day on how they can access our tests and we're excited to announce that we now have a process in place to meet their needs. We will continue to expand this capability over the coming months."

In 2018 the Telehealth market was on-track to grow to 7 million patients with an anticipated growth rate of 18.5% per year. Additional data reports that 64% of Americans were willing to use telehealth services.

It is anticipated that patient directed testing will be fully operational by the end of April. The first test available for online purchase is the Prostate Health Index, an FDA approved test that can help physicians differentiate prostate cancer from benign prostatic conditions in men with elevated PSA. Patients can initiate a test order at  

14.04.19 08:54

417 Postings, 2169 Tage bmueslimycancerrisk

The Worst Cancer diagnosis is a late one ? Yet 40% of Cancers are Still Diagnosed in the later Stages

MyCancerRisk? is a program to help patients and physicians identify cancer risk through blood-based biomarker testing that identifies your personal risk of having or developing cancer. Our individual cancer tests can help find early cancer indicators and provide information needed to pursue the next level of screening and/or encourage the adoption of lifestyle changes that could lower cancer risk.

Finding Cancer Early Saves Lives  

18.04.19 04:37

417 Postings, 2169 Tage bmuesliNews

GeneNews launches national telehealth program

2019-04-17 13:11 ET - News Release

Mr. James Howard-Tripp reports


GeneNews Ltd. has launched its first telehealth program for marketing the Prostate Health Index (PHI) directly to patients nationwide. The Prostate Health Index is a Food and Drug Administration-approved blood test that can help differentiate prostate cancer from benign prostate conditions in men with elevated prostate-specific antigen.

The Prostate Health Index is quickly becoming the "second opinion" for men with elevated PSA who want more information before deciding to move forward with a prostate biopsy. While prostate-specific antigen is currently the most used screening test for prostate cancer, it is widely recognized that PSA results can indicate the possibility of prostate cancer when none is present. The Prostate Health Index utilizes three different PSA markers (PSA, freePSA and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels, and can help men and their physicians decide if a prostate biopsy is indicated.

Addressing an unmet need

"We launched this program to address the hundreds of patient inquiries we get for the Prostate Health Index," commented James Howard-Tripp, chairman and chief executive officer. "Men want a greater say in their treatment and want these tests done at their request, timelines and convenience. When you are at risk for having prostate cancer, you want to know what your next step should be. Now, through a telehealth physician network that is familiar with the clinical utility of the test, we have a solution that can address a patient's immediate need to get tested and to help guide their management."

Studies have shown that approximately 70 per cent of men with an elevated PSA who have a biopsy do not have cancer. The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) guideline for prostate cancer early detection as a blood test to improve specificity for prostate cancer detection.

How it works

The Prostate Health Index is indicated for men aged 50 and older with an elevated PSA between four nanograms per millilitre and 10 nanograms per millilitre. Once an order is submitted, GeneNews will connect the patient with a physician in its U.S.-based telehealth partner network who can prescribe the test after confirming the patient is eligible. GeneNews will then connect the patient with a convenient blood draw location or mobile phlebotomist.

The test is processed at the company's CLIA- and CAP-accredited reference laboratory located in Richmond, Va. Results are reported back to the ordering telehealth physician, who will review the results with the patient. Patients are advised to share their test report with their regular health care professionals so that results can be integrated into their treatment plans.

Patients pay a flat fee of $299, which covers the physician order, blood draw charges, the test and physician consult, as required.

About GeneNews Ltd.

GeneNews is dedicated to developing and commercializing innovative solutions for early cancer detection. The company's mission is to provide advanced diagnostics that can help physicians identify cancer in their patients at the earliest-possible stage, when it is the most curable.

© 2019 Canjex Publishing Ltd. All rights reserved.  

22.04.19 17:54

417 Postings, 2169 Tage bmuesliNews

GeneNews to receive $750,000 in financing from Lind

2019-04-22 08:41 ET - News Release

Mr. James Howard-Tripp reports


Lind Asset Management XI LLC has increased its financing under the first convertible security of the convertible security financing agreement dated May 31, 2018, between GeneNews Ltd. and Lind by $750,000. The agreement was first announced on June 1, 2018.

"This is the second time Lind has agreed to provide additional funding for us," said James R. Howard-Tripp, chairman and chief executive officer of GeneNews. "It is not only good to have their strong support of our objectives but it is also an effective way for us to finance. For reference, our share price was approximately four cents at the time of our January financing with Lind, and the last two conversions were priced at 12.89 cents and 13.57 cents."

Under the terms of the agreement, Lind has advanced an additional $750,000, less a closing fee of $37,500, in consideration for the increase in the first convertible security in the amount of $900,000. The term of the agreement remains at the original 30 months. GeneNews and Lind have also agreed to increase the potential monthly conversion amount under the agreement from $120,000 to $190,000.

In addition, the company will issue 2,552,756 warrants to Lind in respect of the additional financing with an exercise price of 19.09 cents, which is 130 per cent of the five-day volume-weighted average price at April 10, 2019, and exercisable for 36 months. The number of warrants issued in connection with the additional financing is equal to 50 per cent of the $750,000 advanced by Lind divided by the VWAP of the common shares of the company on the Toronto Stock Exchange for the five trading days immediately preceding the closing date.

The company's obligations under the agreement are secured by all of the company's present and after-acquired property other than intellectual property, including a pledge of its equity interests in its subsidiaries.

The increase in financing under the first convertible security and the issuance of securities thereunder have been conditionally approved by the TSX and are subject to satisfaction of customary closing conditions. Additionally, this private placement is not registered in the United States and is not an offer or sale.

About GeneNews Ltd.

GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. The company's mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease.

09.05.19 18:18

417 Postings, 2169 Tage bmuesliNews Company introduces Gary the Prostate to educate consumers about prostate health and prostate cancer awareness TORONTO, ON / ACCESSWIRE / May 9, 2019 / GeneNews Limited (TSX: GEN) ("GeneNews" or the "Company"), a life sciences company specializing in blood-based biomarker tests for early cancer detection, has launched the company's first awareness campaign on prostate cancer. The campaign uses Gary the Prostate to explore prostate cancer symptoms, tests and treatments. "We wanted an approach to get people talking more openly about prostate health and conditions that affect the prostate," said James Howard-Tripp, CEO of GeneNews. "Gary allows us to do this in a relatable and engaging way. Many people feel embarrassed to talk about prostate cancer or even know what the prostate looks like or what it does. This is a way to start the conversation and create awareness." According to the American Cancer Society (ACS), other than skin cancer, prostate cancer is the most common cancer in American men. The ACS estimates that in 2019 there will be approximately 174,650 new cases of prostate cancer and 31,620 deaths. About 1 man in 9 will be diagnosed with prostate cancer during his lifetime. Prostate cancer develops mainly in older men and in African-American men. (1) Learn More About Gary's Campaign at Watch Gary's Campaign Kick-Off at the Link Below ZitatAntwort

GeneNews Bluttest zur Früherkennung von Krebs | - Vollständige Diskussion unter:  

11.06.19 09:08

417 Postings, 2169 Tage bmuesliLizenz Deal mit Oncore
GeneNews signs licensing, services deal with Oncore

2019-06-10 12:32 ET - News Release

Mr. James Howard-Tripp reports


GeneNews Ltd. has signed a global licensing and services agreement with Oncore Pharma Inc.

According to the agreement, Oncore Pharma and its partners will commercialize ColonSentry in all countries other than the Unites States and Canada, under an exclusive licence. GeneNews and Oncore Pharma will work together in Canada. The five-year licensing agreement will initially focus on the Netherlands, Belgium, Luxemburg, Germany, France, Switzerland, Austria, Spain, Monaco, Italy, Portugal, the United Kingdom, Ireland, Norway, Sweden, Finland, Denmark, Israel and the United Arab Emirates, as well as Canada. The agreement with Oncore Pharma aims to deploy a total of 1.75 million tests over the next five years.

Under the terms of the agreement, GeneNews will receive a fixed fee per ColonSentry test, a special royalty payment equal to 10 per cent of Oncore's yearly profits and receive one million shares of Oncore Pharma. The processing of ColonSentry will be done in GeneNews's Richmond, Va., laboratory.

"We created Oncore Pharma to focus specifically on research, development and commercialization of Oncology products and ColonSentry is exactly the type of diagnostic test the market needs and our customers demand," said Dr. Nadeem Saddiqui, the chief scientific officer and chief executive officer of Oncore Pharma Inc. "We have been researching various diagnostic technologies and the science behind GeneNews's ColonSentry is extraordinary and ahead of any competitors by far," added Dr. Saddiqui.

"We are delighted to be working with Oncore Pharma and their partners and believe the relationship will help us more speedily reach our short-term and long-term objectives," said James Howard-Tripp, chairman and CEO of GeneNews. "The Oncore Pharma team's experience in bringing products to market, coupled with their scientific knowledge in our space, provides our company with a great advantage," added Mr. Howard-Tripp. "We are to begin immediately."

   Antwort einfügen - nach oben

Online Brokerage über Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von!


Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Euro US-Dollar
Wirecard AG747206
Daimler AG710000
Ballard Power Inc.A0RENB
Aurora Cannabis IncA12GS7
Deutsche Bank AG514000
Microsoft Corp.870747
Apple Inc.865985
thyssenkrupp AG750000